When I last wrote my blog post, “New Jersey Marijuana Social Lounges,” in November 2018, the New Jersey adult-use recreational bill was in its infancy. Now that the state has finally legalized marijuana under the New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act (“CREAMMA”), I am duty-bound to update the blog on “cannabis consumption areas” or “CCAs” as defined in CREAMMA.» Read More
As in many industries, early-stage companies in the cannabis space need capital. With traditional financing limited, outside investment becomes a possibility, but in seeking investors, the company needs to comply with federal and state securities laws. A September 2018 Investor Alert from the United States Securities and Exchange Commission provides warning signs for investors about the uptick in fraud in the cannabis space.» Read More
After several stalled attempts to pass a recreational marijuana law through legislation in New Jersey, voters will finally get the chance to decide the issue at the polls in November 2020.
On December 16, 2019, the New Jersey legislature approved a referendum putting the question of whether to legalize adult-use marijuana on the state’s 2020 general election ballot.» Read More
Unlike other states, such as Colorado, California, and even Maryland, here in New Jersey, our laws concerning the advertising and marketing of cannabis products are sparse.
The New Jersey medicinal marijuana program continues to expand its list of qualifying conditions.
As more New Jersey residents become qualified for medical marijuana and more Alternative Treatment Centers (ATCs) open their doors across the Garden State, regulations for the disposal of waste from marijuana operations are being considered.» Read More
Fraud and scam artists have been and will always be present in any industry or business community (with Enron and Bernie Madoff only being two of the most recent such examples), and the cannabis industry has already seen a few such characters in its short (legal) history, with more certainly to follow.» Read More
As one might expect from the title “Federal Food, Drug, and Cosmetic Act,” the Food and Drug Administration (“FDA”) has broad authority.
Since the approval of the drug EPIDIOLEX® CV, which has cannabidiol (“CBD”) as an active ingredient, the FDA has taken the position that some products containing CBD are unapproved drugs or unapproved dietary supplements.» Read More
Owners and operators of a company (whether organized as a corporation or a limited liability company (LLC)) involved in the cannabis industry must remember that the company is also a business that is a separate legal entity.